{
    "clinical_study": {
        "@rank": "82298", 
        "arm_group": [
            {
                "arm_group_label": "Group 1"
            }, 
            {
                "arm_group_label": "Group 2"
            }
        ], 
        "brief_summary": {
            "textblock": "This cross-sectional epidemiologic study will measure physician and patient awareness and\n      understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert\n      card."
        }, 
        "brief_title": "Patient and Physician Knowledge of Key Safety Messages", 
        "completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Anticoagulation", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Physicians eligibility:\n\n          -  Prescription of rivaroxaban in the past 6 months for adult patients for the\n             Prevention of stroke and systemic embolism with non-valvular atrial fibrillation\n             (SPAF) or Treatment of deep venous thrombosis (DVT) and prevention of recurrent DVT\n             and pulmonary embolism (PE) following an acute DVT.\n\n        Patient eligibility:\n\n          -  Use of rivaroxaban for SPAF or DVT within the previous 3 months; aged 18 years and\n             above; able to understand and complete the consent form and patient questionnaire.\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Physicians of various specialties; patients treated in primary care and specilized\n        clinical practices."
            }
        }, 
        "enrollment": {
            "#text": "4000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907048", 
            "org_study_id": "16167", 
            "secondary_id": "XA1202"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1", 
                "description": "Survey to measure physician awareness and understanding of the key messages in the prescriber guide.", 
                "intervention_name": "Rivaroxaban (Xarelto, BAY59-7939)", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Group 2", 
                "description": "Survey to measure patient awareness and understanding of the key messages in the patient card.", 
                "intervention_name": "Rivaroxaban (Xarelto, BAY59-7939)", 
                "intervention_type": "Behavioral"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Survey", 
            "Effectiveness of risk minimization measures", 
            "Rivaroxaban", 
            "Anticoagulants"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "number_of_groups": "2", 
        "official_title": "Xarelto (Rivaroxaban) - Risk Minimisation Plan Evaluation: Patient and Physician Knowledge of Key Safety Messages", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Knowledge and understanding among physicians regarding key safety information contained in the prescriber guide assessed by web-based questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Up to 18 months"
            }, 
            {
                "measure": "Knowledge and understanding of patients regarding the key safety information contained in the patient alert card assessed by paper-based questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Up to 18 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907048"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "collaborator": {
                "agency": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C., RTI Health Solutions", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}